OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II. Compare remission relapse rates in these patients after glucocorticoid therapy with or without methotrexate. III. Determine whether adjunctive use of methotrexate lowers cumulative dose and duration of glucocorticoid therapy and whether there is less treatment related morbidity and mortality. IV. Demonstrate the feasibility of long term, double blind, placebo controlled, randomized, multicenter trials for treatment of systemic vasculitides.

Condition	Treatment or Intervention	Phase
Giant Cell Arteritis	Drug: methotrexate  Drug: prednisone	Phase II

Further Study Details: 

Expected Total Enrollment:  300

PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study. Patients are randomized into initial therapy with prednisone plus weekly placebo or prednisone plus weekly oral methotrexate. Patients who do not respond to treatment within 5 days are taken off study. If methotrexate toxicity dose not occur after 2 weeks, methotrexate is increased by one tablet per week until a maximum tolerated dose (MTD) is achieved. The MTD of methotrexate or the matching placebo dose is continued for 12 months in the absence of toxicity. Once 12 continuous months of remission are achieved, methotrexate or placebo is tapered to discontinuation. Patients are followed for 1-6 years.

Ages Eligible for Study:  50 Years and above,  Genders Eligible for Study:  Both

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of giant cell arteritis (GCA) by at least one of the following:

• Temporal artery biopsy confirming GCA Symptoms of GCA (including new onset (within 6 months) symptoms of headaches, tenderness of the scalp or the temporal arteries, visual loss due to retinal ischemic optic neuropathy or otherwise unexplained tongue or jaw pain) and an aortic angiogram that revealed stenotic and/or aneurysmal disease of the aorta and its principal branches
• Symptoms of polymyalgia rheumatica plus ischemic optic neuropathy, newly identified tenderness over a temporal artery, or new onset of tongue or jaw pain

Westergren erythrocyte sedimentation rate of at least 40 nm in one hour

--Prior/Concurrent Therapy--

Endocrine therapy: No greater than 20 days since initiation of prednisone therapy

Other: No concurrent sulfa drugs or nonsteroidal antiinflammatory drugs

--Patient Characteristics--

Hematopoietic:

• WBC at least 4,000/mm3
• Platelet count at least 120,000/mm3
• No acute or chronic liver disease

Hepatic:

• Alkaline phosphatase no greater than 2 times upper limit of normal
• No other reproducible abnormal liver function test

Renal: Creatinine less than 2.0 mg/dL

Other:

• HIV negative
• No symptomatic peptic ulcer disease within the last 3 months
• Hepatitis B or C antigen negative
• No alcohol use in excess of 2 ounces of 100 proof liquor or 1 beer or its equivalent per week
• No insulin dependent diabetes mellitus plus morbid obesity (greater than 33% over ideal body weight)
• No recently (less than 6 months) diagnosed malignancy
• Not pregnant or nursing
• Adequate contraception required of all fertile patients

Study chairs or principal investigators

Gary Stuart Hoffman,  Study Chair,  Cleveland Clinic Foundation Hospital   

Study ID Numbers:  199/13298; CCF-RPC-4586; CCF-FDR001040; DPT-32-0-48
Record last reviewed:  March 1999
Last Updated:  October 13, 2004
Record first received:  February 24, 2000
ClinicalTrials.gov Identifier:  NCT00004686
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08